Economic and Cost-effectiveness Aspects of Vaccines in Combating Antibiotic Resistance

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2023 May 30

PMID 37248971

Authors

Tatenda Yemeke

Hui-Han Chen

Sachiko Ozawa

Affiliations

Soon will be listed here.

Abstract

Antimicrobial resistance (AMR) is a global public health threat causing substantial morbidity and mortality as well as significant economic costs. Vaccines can contribute to combating antimicrobial resistance by reducing the incidence of resistant disease cases and lowering overall antibiotic use. Greater utilization and investments in vaccines as a tool for combating AMR might be hampered by limited economic evidence demonstrating the AMR-related value of vaccines. We reviewed the existing literature to assess the state of evidence. We found two modeling studies that provided estimates of AMR-related costs averted by pneumococcal vaccination and a few cost-effectiveness studies that exclusively focused on serotype replacement effects on overall vaccine cost-effectiveness. We did not find any cost-effectiveness studies that directly examined the cost-effectiveness of vaccines in slowing the development of AMR. Further evidence on the cost-effectiveness and economic value of vaccines in controlling AMR can help inform resource allocation decisions and guide development priorities.

Citing Articles

Leuconostoc lactis strain APC 3969 produces a new variant of cyclic bacteriocin leucocyclicin Q and displays potent anti-Clostridium perfringens activity.

de Farias F, Soria M, OConnor P, Huang X, Buttimer C, Kamilari E Sci Rep. 2025; 15(1):6372.

PMID: 39984510 PMC: 11845615. DOI: 10.1038/s41598-025-89450-x.

Antimicrobial Resistance in the Context of Animal Production and Meat Products in Poland-A Critical Review and Future Perspective.

Wisniewski P, Trymers M, Chajecka-Wierzchowska W, Tkacz K, Zadernowska A, Modzelewska-Kapitula M Pathogens. 2025; 13(12.

PMID: 39770382 PMC: 11676418. DOI: 10.3390/pathogens13121123.

A Structured Narrative Literature Review of the Broader Value of Adult Immunisation Programmes.

El Banhawi H, Bell E, Neri M, Brassel S, Chowdhury S, Steuten L Vaccines (Basel). 2024; 12(8).

PMID: 39203978 PMC: 11359156. DOI: 10.3390/vaccines12080852.

Dietary supplementation with mulberry leaf flavonoids and carnosic acid complex enhances the growth performance and antioxidant capacity via regulating the p38 MAPK/Nrf2 pathway.

Liu C, Huang H, Chen Y, Zhou Y, Meng T, Tan B Front Nutr. 2024; 11:1428577.

PMID: 39139650 PMC: 11319276. DOI: 10.3389/fnut.2024.1428577.

From Protection to Prevention: Redefining Vaccines in the Context of Antimicrobial Resistance.

Sallam M, Snygg J, Allam D, Kassem R Cureus. 2024; 16(5):e60551.

PMID: 38887339 PMC: 11181895. DOI: 10.7759/cureus.60551.

References

Bell E, Neri M, Steuten L . Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward. Appl Health Econ Health Policy. 2021; 20(1):105-117. PMC: 8458004. DOI: 10.1007/s40258-021-00683-z. View

Stenberg K, Hanssen O, Edejer T, Bertram M, Brindley C, Meshreky A . Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries. Lancet Glob Health. 2017; 5(9):e875-e887. PMC: 5554796. DOI: 10.1016/S2214-109X(17)30263-2. View

Shrestha P, Cooper B, Coast J, Oppong R, Do Thi Thuy N, Phodha T . Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018; 7:98. PMC: 6085682. DOI: 10.1186/s13756-018-0384-3. View

Lu E, Chen H, Zhao H, Ozawa S . Health and economic impact of the pneumococcal conjugate vaccine in hindering antimicrobial resistance in China. Proc Natl Acad Sci U S A. 2021; 118(13). PMC: 8020802. DOI: 10.1073/pnas.2004933118. View

Yahiaoui R, Bootsma H, den Heijer C, Pluister G, Paget W, Spreeuwenberg P . Distribution of serotypes and patterns of antimicrobial resistance among commensal Streptococcus pneumoniae in nine European countries. BMC Infect Dis. 2018; 18(1):440. PMC: 6116386. DOI: 10.1186/s12879-018-3341-0. View

Weinberger D, Malley R, Lipsitch M . Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011; 378(9807):1962-73. PMC: 3256741. DOI: 10.1016/S0140-6736(10)62225-8. View

Kulpeng W, Leelahavarong P, Rattanavipapong W, Sornsrivichai V, Baggett H, Meeyai A . Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context?. Vaccine. 2013; 31(26):2839-47. PMC: 4667720. DOI: 10.1016/j.vaccine.2013.03.047. View

Sundaram N, Chen C, Yoong J, Luvsan M, Fox K, Sarankhuu A . Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia. Vaccine. 2017; 35(7):1055-1063. PMC: 5297341. DOI: 10.1016/j.vaccine.2016.12.070. View

Hanage W, Finkelstein J, Huang S, Pelton S, Stevenson A, Kleinman K . Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics. 2010; 2(2):80-4. PMC: 2963072. DOI: 10.1016/j.epidem.2010.03.005. View

10.

Kim S, Chung D, Song J, Baek J, Thamlikitkul V, Wang H . Changes in serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates from adult patients in Asia: Emergence of drug-resistant non-vaccine serotypes. Vaccine. 2019; 38(38):6065-6073. DOI: 10.1016/j.vaccine.2019.09.065. View

11.

Ayieko P, Griffiths U, Ndiritu M, Moisi J, Mugoya I, Kamau T . Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLoS One. 2013; 8(6):e67324. PMC: 3691111. DOI: 10.1371/journal.pone.0067324. View

12.

Lo S, Gladstone R, van Tonder A, Lees J, du Plessis M, Benisty R . Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis. 2019; 19(7):759-769. PMC: 7641901. DOI: 10.1016/S1473-3099(19)30297-X. View

13.

Ozawa S, Chen H, Rao G, Eguale T, Stringer A . Value of pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): Case study using DREAMR in Ethiopia. Vaccine. 2021; 39(45):6700-6711. DOI: 10.1016/j.vaccine.2021.04.024. View

14.

Obolski U, Lourenco J, Thompson C, Thompson R, Gori A, Gupta S . Vaccination can drive an increase in frequencies of antibiotic resistance among nonvaccine serotypes of . Proc Natl Acad Sci U S A. 2018; 115(12):3102-3107. PMC: 5866575. DOI: 10.1073/pnas.1718712115. View

15.

Jit M, Ng D, Luangasanatip N, Sandmann F, Atkins K, Robotham J . Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. BMC Med. 2020; 18(1):38. PMC: 7059710. DOI: 10.1186/s12916-020-1507-2. View

16.

Klugman K, Black S . Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. Proc Natl Acad Sci U S A. 2018; 115(51):12896-12901. PMC: 6304973. DOI: 10.1073/pnas.1721095115. View

17.

Standaert B, Rappuoli R . 2. How is the economic assessment of vaccines performed today?. J Mark Access Health Policy. 2018; 5(1):1335163. PMC: 5956288. DOI: 10.1080/20016689.2017.1335163. View

18.

. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

19.

Lochen A, Croucher N, Anderson R . Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020; 10(1):18977. PMC: 7643077. DOI: 10.1038/s41598-020-75691-5. View

20.

Wang X, Saha A, Zhang X . Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia. Cost Eff Resour Alloc. 2017; 15:17. PMC: 5568314. DOI: 10.1186/s12962-017-0079-2. View